Endoglin expression in upper urinary tract urothelial carcinoma is associated with intravesical recurrence after radical nephroureterectomy

To evaluate the expression and prognostic significance of endoglin in patients with upper urinary tract urothelial carcinoma.

[1]  E. Kikuchi,et al.  Evidenced‐based clinical practice guideline for upper tract urothelial carcinoma (summary – Japanese Urological Association, 2014 edition) , 2015, International journal of urology : official journal of the Japanese Urological Association.

[2]  N. Nonomura,et al.  Preoperative risk stratification for cancer-specific survival of patients with upper urinary tract urothelial carcinoma treated by nephroureterectomy , 2015, International Journal of Clinical Oncology.

[3]  J. Hicks,et al.  Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma. , 2013, Human pathology.

[4]  K. Fujita,et al.  Preoperative serum sodium is associated with cancer‐specific survival in patients with upper urinary tract urothelial carcinoma treated by nephroureterectomy , 2013, International journal of urology : official journal of the Japanese Urological Association.

[5]  David A. Green,et al.  Urothelial carcinoma of the bladder and the upper tract: disparate twins. , 2013, The Journal of urology.

[6]  David S Mendelson,et al.  A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer , 2012, Clinical Cancer Research.

[7]  C. Streutker,et al.  Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis. , 2012, Human pathology.

[8]  Y. Okada,et al.  The Prognostic Significance of Vasohibin-1 Expression in Patients with Upper Urinary Tract Urothelial Carcinoma , 2012, Clinical Cancer Research.

[9]  E. Kikuchi,et al.  Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. , 2011, Urology.

[10]  S. Saxena,et al.  Role of Tumor Suppressor and Angiogenesis Markers in Prediction of Recurrence of Non Muscle Invasive Bladder Cancer , 2011, Pathology & Oncology Research.

[11]  G. Fleuren,et al.  Expression of endoglin (CD105) in cervical cancer , 2009, British Journal of Cancer.

[12]  A. Partin,et al.  Endoglin (CD105) as a urinary and serum marker of prostate cancer , 2009, International journal of cancer.

[13]  Jeffrey K. Cohen,et al.  Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. , 2007, American journal of clinical pathology.

[14]  P. Kyzas,et al.  Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma , 2006, Virchows Archiv.

[15]  K. Grankvist,et al.  Endoglin (CD105) expression in human renal cell carcinoma , 2006, BJU international.

[16]  J. Silverman,et al.  Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer , 2004, Modern Pathology.

[17]  L. Santos,et al.  Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  P. Bonnier,et al.  CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. , 2003, American journal of clinical pathology.

[19]  P. Tamboli,et al.  The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Sun‐Ju Lee,et al.  Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors. , 2001, Oncology reports.

[21]  M. Tabata,et al.  Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  B. Brooke,et al.  Defective angiogenesis in mice lacking endoglin. , 1999, Science.

[23]  A. Harris,et al.  Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. , 1997, Cancer research.